Literature DB >> 21218361

A qualitative study of the impact of living with neurofibromatosis type 2.

Chirag M Patel1, Ros Ferner, Elizabeth A Grunfeld.   

Abstract

Neurofibromatosis type 2 (Nf2) is an inherited autosomal dominant syndrome characterised by the development of nervous system tumours, ocular abnormalities and skin tumours. Symptoms of Nf2 can vary depending on the size and location of the tumour and include hearing loss, balance deficits and facial palsy. This study explored the physical, emotional and social impact of Nf2. Six patients were recruited through a neurofibromatosis clinic and underwent a semi-structured interview. Interviews were recorded and analysed using Framework analysis. Participants spoke of the negative impact of Nf2 on daily activities, including work. Social isolation resulted from the avoidance of social situations and was often a consequence of difficulties with communication due to loss of hearing. Patients expressed a range of negative emotional reactions in response to their diagnosis and the impact of the disease. Furthermore, the findings highlighted the important role of partners and family who were relied on for physical as well as emotional and psychological support. Patients also expressed frustration at the limited awareness of Nf2 among health professionals and a desire for improved access to information on Nf2 within their local community.

Entities:  

Mesh:

Year:  2011        PMID: 21218361     DOI: 10.1080/13548506.2010.516363

Source DB:  PubMed          Journal:  Psychol Health Med        ISSN: 1354-8506            Impact factor:   2.423


  6 in total

1.  The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.

Authors:  Rachael E Hornigold; John F Golding; Guy Leschziner; Rupert Obholzer; Michael J Gleeson; Nick Thomas; Daniel Walsh; Shakeel Saeed; Rosalie E Ferner
Journal:  J Neurol Surg B Skull Base       Date:  2012-04

2.  Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Filippo G Giancotti; Alexander Filatov; Anna Derman; Tsivia Hochman; Judith D Goldberg; Emilio Vega; Jeffrey H Wisoff; John G Golfinos; Amanda Merkelson; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

3.  Cochlear Implantation in Vestibular Schwannoma: A Systematic Literature Review.

Authors:  Kent Tadokoro; Matthew Robert Bartindale; Nadeem El-Kouri; Dennis Moore; Christopher Britt; Matthew Kircher
Journal:  J Neurol Surg B Skull Base       Date:  2021-06-08

4.  Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.

Authors:  Rosalie E Ferner; Adam Shaw; D Gareth Evans; Dympna McAleer; Dorothy Halliday; Allyson Parry; F Lucy Raymond; Juliette Durie-Gair; C Oliver Hanemann; Rachel Hornigold; Patrick Axon; John F Golding
Journal:  J Neurol       Date:  2014-03-12       Impact factor: 4.849

Review 5.  Magnetic Resonance Imaging in a Neurofibromatosis Type 2 Patient with a Novel MRI-Compatible Auditory Brainstem Implant.

Authors:  Matthew Shew; Judson Bertsch; Paul Camarata; Hinrich Staecker
Journal:  J Neurol Surg Rep       Date:  2017-01

6.  Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.